525 related articles for article (PubMed ID: 17516397)
1. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
[TBL] [Abstract][Full Text] [Related]
3. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
Shamsi Meymandi S; Javadi A; Dabiri S; Shamsi Meymandi M; Nadji M
Arch Iran Med; 2011 Jul; 14(4):238-43. PubMed ID: 21726098
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
Firooz A; Khamesipour A; Ghoorchi MH; Nassiri-Kashani M; Eskandari SE; Khatami A; Hooshmand B; Gorouhi F; Rashighi-Firoozabadi M; Dowlati Y
Arch Dermatol; 2006 Dec; 142(12):1575-9. PubMed ID: 17178983
[TBL] [Abstract][Full Text] [Related]
5. Allopurinol in the treatment of American cutaneous leishmaniasis.
Martinez S; Marr JJ
N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.
Arevalo I; Ward B; Miller R; Meng TC; Najar E; Alvarez E; Matlashewski G; Llanos-Cuentas A
Clin Infect Dis; 2001 Dec; 33(11):1847-51. PubMed ID: 11692295
[TBL] [Abstract][Full Text] [Related]
7. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
8. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
9. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
Sadeghian G; Nilfroushzadeh MA; Iraji F
Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Munir A; Janjua SA; Hussain I
Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
[TBL] [Abstract][Full Text] [Related]
12. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
Esfandiarpour I; Dabiri SH
Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170
[TBL] [Abstract][Full Text] [Related]
13. Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico.
Vargas-Gonzalez A; Canto-Lara SB; Damian-Centeno AG; Andrade-Narvaez FJ
Am J Trop Med Hyg; 1999 Dec; 61(6):960-3. PubMed ID: 10674678
[TBL] [Abstract][Full Text] [Related]
14. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
Momeni AZ; Aminjavaheri M
Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
[TBL] [Abstract][Full Text] [Related]
16. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
Saldanha AC; Romero GA; Merchan-Hamann E; Magalhães AV; Macedo Vde O
Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
Bogenrieder T; Lehn N; Landthaler M; Stolz W
Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089
[TBL] [Abstract][Full Text] [Related]
18. Early enlargement of an ulcerated area during leishmaniasis treatment with meglumine antimoniate in Brazil.
Romero GA; Molinet FJ; Noronha EF
Trans R Soc Trop Med Hyg; 2013 Apr; 107(4):266-8. PubMed ID: 23315614
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
20. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
